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IntroductIon
During B cell development in the fetal liver (FL), hematopoi-
etic stem cells, defined as lineage-negative Sca-1+ c-Kit+ cells, 
mature to gain expression of IL-7Rα (CD127) and are known 
as common lymphoid progenitor (CLP) cells (Egawa et al., 
2001; Mebius et al., 2001). However, this population is multi-
potent and still contains cells with potential for both lymphoid 
and myeloid lineages (Mebius et al., 2001). Commitment to 
the B cell lineage first occurs on embryonic day 12.5 (E12.5), 
as cells mature to initially express CD19 or B220 and are de-
fined as either B-1 (CD19+B220lo-neg) or B-2 (CD19−B220+) 
lineage cells (Egawa et al., 2001; Dorshkind and Monteci-
no-Rodriguez, 2007; Montecino-Rodriguez and Dorshkind, 
2012). B-1 cell development is more prominent in the FL and 
fetal BM, whereas B-2 cells are mainly produced in the adult 
BM (Montecino-Rodriguez and Dorshkind, 2012).
Both B-1 and B-2 progenitors mature into B220+CD19+ 
double-positive cells, which undergo immunoglobulin heavy 
chain gene rearrangement to give rise to the first cells that 
express cell surface µH (pre-BCR; Dorshkind and Monteci-
no-Rodriguez, 2007; Montecino-Rodriguez and Dorshkind, 
2012). This pre–B cell population can also be identified by 
cell surface expression of BP-1, before rearrangement of the 
light chain locus and cell surface expression of IgM (Hardy 
and Hayakawa, 2001; Dorshkind and Montecino-Rodriguez, 
2007; Montecino-Rodriguez and Dorshkind, 2012).
Here, we investigate the role of Sonic hedgehog (Hh 
[Shh]) and the transcription factor Gli3 in the regulation of 
B cell development in the FL. Shh is one of three mammalian 
Hh proteins (Shh, Indian Hh [Ihh], and Desert Hh [Dhh]) 
that share a common signaling pathway (Ingham et al., 2011; 
Ramsbottom and Pownall, 2016). Hh proteins signal by bind-
ing to their cell surface receptor Patched1 (Ptch1), thereby 
releasing Ptch1’s repression of Smoothened (Smo), allowing 
Smo to transduce the Hh signal. At the end of the signal-
ing pathway are the Hh-responsive transcription factors Gli1, 
Gli2, and Gli3 (Ingham et al., 2011). Gli1 is itself an Hh-target 
gene and encodes an activator of transcription (Park et al., 
2000), whereas Gli2 and Gli3 can be processed to function 
as transcriptional activators (Gli2A/Gli3A, in the presence of 
Hh pathway activation) or transcriptional repressors (Gli2R/
Gli3R, in the absence of Hh pathway activation; Sasaki et al., 
1999). Gli2 is required to initiate the Hh signal and functions 
largely as a transcriptional activator in vivo (Park et al., 2000; 
Bai et al., 2002). In contrast, Gli3 functions predominantly 
as a transcriptional repressor in vivo (Wang et al., 2000). The 
pathway has multiple positive and negative feedback mech-
anisms, and Ptch1 is itself an Hh-target gene, functioning 
to sequester Hh proteins and limit activation of the path-
way (Ingham et al., 2011).
Gli3 can have both Hh-independent and Hh-dependent 
functions (te Welscher et al., 2002; Hager-Theodorides et al., 
2009). Gli3R functions to limit Hh pathway activation in 
many tissues (Wang et al., 2000; Ahn and Joyner, 2004; Hag-
er-Theodorides et al., 2009). There are at least two distinct 
mechanisms by which Gli3R can limit Hh signaling: it may 
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repress expression of Hh genes in the Hh-producing cell via 
repression of Hh-activating genes, thus limiting Hh protein 
concentration in the tissue. For example, during prepattern-
ing of the limb bud, Gli3R spatially limits the expression of 
dHand, an activator of Shh gene expression (te Welscher et 
al., 2002). Alternatively, when Gli3 is expressed in the sig-
nal-receiving cell, the concentration of Gli3R in a given 
cell increases the further away the cell is located from the 
Hh-secreting source, resulting in correspondingly increased 
repression of Hh-target genes (Wang et al., 2000; te Welscher 
et al., 2002). In fact, in many tissues, such as thymus and limb 
bud, Shh and Gli3 have opposing functions, with Shh de-
ficiency and Gli3 deficiency giving opposite phenotypes 
(Wang et al., 2000; Shah et al., 2004; Hager-Theodorides et 
al., 2005, 2009; Barbarulo et al., 2016). Here, we show that 
Gli3 expressed in the FL stroma promotes B-lineage commit-
ment of hematopoietic progenitor cells and B cell develop-
ment by suppression of Shh signaling.
rESuLtS
Impaired B-lineage commitment in the Gli3-deficient FL
The Hh-responsive transcription factor Gli3 is expressed in 
mouse FL (Cridland et al., 2009) and human FL and BM 
(Fig. S1 A; Su et al., 2004). Microarray expression profiles 
from the Immgen database show expression of Smo, Ptch1, 
and the Gli transcription factors in mouse E15 FL hemato-
poietic stem cells, CLPs, and pro–B (CD19+µH−) and pre– 
B (CD19+µH+) cells (Fig. S1, B–F; Heng et al., 2008). There-
fore, to investigate the role of Gli3 in fetal B cell development, 
we analyzed B-lineage markers in Gli3−/−, Gli3+/−, and Gli3+/+ 
(WT) littermate E18.5 FL. We found statistically significant 
gene dose–dependent decreases in the proportions of the 
CD19+ cells, B220+ cells, and CD19+B220+ cells in the E18.5 
Gli3-mutant FL (Fig. 1, A–E). The Gli3−/− FL also showed 
a significant decrease in the proportion of CD19−B220+ B2 
progenitor cells (Fig. 1, C and E). Additionally, the proportion 
of CD19+ cells that expressed the cell surface heavy chain µH 
was significantly reduced in the Gli3-mutant FL compared 
with WT (Fig. 1, D and F).
We further characterized early B cell development by 
staining against the B-lineage marker CD93 and then subdi-
viding the CD93+ population by expression of ckit, CD127, 
heat stable antigen (HSA), CD43, and BP-1, in addition to 
CD19 and µH expression, to identify four fractions of in-
creasing maturity (Fig. 1, G and H). The overall proportion of 
CD93+ cells (B lineage committed) was significantly reduced 
in the Gli3−/− FL compared with WT (Fig. 1 G). Gating on 
these CD93+ cells, the proportion of the early ckit+CD127+ 
population (fraction A) was also significantly reduced in the 
Gli3−/− FL compared with WT, as were the later CD43+C-
D19+HSA+BP-1+ (fraction D) and CD19+HSA+µH+ popu-
lations (fraction E; Fig. 1 H).
As Gli3 deficiency influenced early B cell maturation 
and reduced the proportion of µH+ B-lineage cells, we used 
quantitative RT-PCR (Q-RT-PCR) to test whether heavy 
chain rearrangements were reduced in FACS-sorted CD19+ 
cells from Gli3−/− and WT littermates. We quantified rear-
rangements between two different VH to JH segments and 
found no evidence for reduced gene rearrangement in devel-
oping B cells from the Gli3-deficient FL (Fig. 1 I).
Gli3 activity is not required for B cell development in the 
hematopoietic compartment of the FL
To investigate whether the reduction in B cell development 
in the Gli3-mutant FL is caused by cell-intrinsic Gli3 activity 
in the hematopoietic compartment or caused by Gli3 activity 
in the nonhematopoietic compartment (stroma), we used the 
Cre-loxP system to conditionally delete Gli3 from the hema-
topoietic lineage in Gli3fl/fl VavCre+ (Gli3coKO) embryos. We 
found no significant difference in B cell differentiation be-
tween the control (Cre negative) and Gli3coKO FL, and the 
proportion of cells that expressed CD19, B220, and BP-1 was 
not different between control and Gli3coKO (Fig.  1, J–L). 
Therefore, Gli3 activity in the FL stroma, rather than hema-
topoietic cell–intrinsic activity, regulates B cell differentiation.
Increased Hh signaling in the Gli3-mutant FL
As Gli3 can have Hh-independent and Hh-dependent 
functions and can act to limit Hh pathway activation, we 
tested whether the Gli3-mutant FL had increased levels of 
Hh pathway activation by measuring the transcription of 
Hh pathway components and target genes by Q-RT-PCR 
from the tissue (Fig. 2, A–D). The Hh-target genes, the tran-
scription factor Gli1, and the Hh receptor Ptch1 were in-
creased in the Gli3−/− FL compared with WT, as was the 
Hh-responsive transcription factor Gli2 (Fig. 2, A–C). Tran-
scription of Shh was also increased, consistent with Gli3 
functioning to repress Shh expression (Fig. 2 D). Then, we 
FACS-sorted CD45+CD19+ (B lineage) and nonhematopoi-
etic CD45− (stroma) cells from Gli3−/− and littermate WT FL 
and compared expression of Hh pathway components and 
target genes (Fig. 2, E–H). Expression of Gli1 was higher in 
nonhematopoietic WT cells than in the CD19+ population, 
and its expression was increased in the Gli3-deficient popu-
lations, with greater increase in the nonhematopoietic (stro-
mal) Gli3-deficient compartment (Fig. 2 E). Gli2 expression 
was approximately fivefold higher in the stromal cells of the 
Gli3-deficient FL compared with WT and was relatively very 
low in the CD19+ fraction (Fig.  2  F). In contrast, expres-
sion of Ptch1 was increased in both populations sorted from 
Gli3−/− compared with WT FL (Fig. 2 G). Expression of Shh 
was greatly up-regulated in the nonhematopoietic (stromal) 
component of the Gli3−/− FL compared with WT, consistent 
with Gli3 functioning to repress Shh expression in the FL 
stroma (Fig. 2 H) and with a previous study on expression 
of Shh by Dlk+ hepatoblasts (Hirose et al., 2009). Although 
Gli3 and Gli2 can have overlapping or redundant functions in 
some tissues, we found no evidence for redundancy between 
Gli3 and Gli2 in repression of Shh expression in the stroma; 
in the absence of Gli3, Shh was up-regulated.
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Figure 1. B lineage development in E18.5 and E17.5 Gli3+/+, Gli3+/−, and Gli3−/− and E17.5 Gli3fl/flVavcre+ FL. (A–F) Flow cytometry profile of 
E18.5 FL from Gli3+/+ (WT), Gli3+/−, and Gli3−/− littermates after red blood cell lysis from a representative experiment. (A–D) Dot plots: SSC against CD19 (A), 
SSC against B220 (B), CD19 versus B220 (C), and SSC against μH gated on CD19+ cells (D). (E and F) Bar charts: mean percentage of FL populations, relative 
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Given that transcription of Hh-target genes and Shh 
were up-regulated in the absence of Gli3, whereas the 
B cell progenitor populations were reduced, we tested 
whether developing B cells and stromal cells are undergo-
ing active Hh signaling in the FL. We used Gli binding site 
(GBS)–GFP-transgenic reporter mice, in which GFP is ex-
pressed when activator forms of Gli proteins bind to the GBS 
in the transgene, to measure active Hh-dependent transcrip-
tion (Balaskas et al., 2012). Approximately 4% of CD19+ cells 
expressed GFP in the WT FL (Fig. 2 I), and a higher level 
of GFP expression of ∼8% and ∼9% was observed in the 
CD19+B220− (B-1 progenitors) and CD19−B220+ (B-2 pro-
genitors), respectively (Fig. 2, J–K), suggesting that Hh signal-
ing is higher in cells transitioning from the immature B1 and 
B2 progenitor stages toward the CD19+B220+ stage. High 
proportions of nonhematopoietic (CD45−) stromal FL cells 
(∼57%) and of the epithelial cell adhesion molecule+ subset 
of CD45− FL cells (∼53%) expressed GFP (Fig. 2 L), confirm-
ing the Q-RT-PCR data, which indicated that Hh signaling 
is also active in the nonhematopoietic stromal compartment 
(Fig. 2, E and G). The proportion of GFP-expressing CD19+, 
CD19+B220−, and CD19−B220+ cells was significantly in-
creased in the Gli3−/− compared with WT (Fig. 2, I–K and 
M). However, there was no significant difference in the pro-
portion of GFP+ cells between Gli3+/− and WT (Fig. 2 M). 
The mean fluorescence intensity (MFI) of the CD19+GFP+ 
cells significantly increased from WT to Gli3+/− and from WT 
to Gli3−/−, indicating higher Hh-dependent transcription in 
individual cells (Fig. 2 M).
Hh signaling is a negative regulator of 
fetal B cell development
The Gli3−/− FL had increased Shh transcription, increased 
expression of Hh-target genes, and increased GFP expres-
sion in developing B cells in the GBS-GFP reporter–trans-
genic embryos (Fig.  2). Thus, we tested whether increased 
Hh signaling reduces B cell development in vitro. We assessed 
B cell populations after 4 d in WT E17.5 FL organ cultures 
(FLOCs) treated with recombinant Shh (rShh) alone, with 
recombinant Hh-interacting protein (Hhip [rHhip]; to bind 
and neutralize endogenous Hh proteins in the cultures) alone, 
or treated with both rShh and rHhip, compared with control 
nontreated FLOCs (Fig. 3, A and B). Treatment with rShh sig-
nificantly reduced the proportion of CD19+ cells from 26% 
in control cultures to 19.6% in rShh-treated FLOCs, whereas 
neutralization of endogenous Hh proteins by treatment with 
rHhip significantly increased the proportion of CD19+ cells 
to 31.3%. To confirm the specificity of the reagents and that 
the inhibitory effect of rShh was not the result of nonspe-
cific toxicity, we added both reagents together and found that 
the proportion of CD19+ cells was not significantly differ-
ent from control cultures (Fig. 3, A and B). The proportion 
of the B220+CD19+ and CD19+µH+ populations were also 
both significantly decreased compared with the control by 
rShh treatment and increased by rHhip treatment in FLOCs 
(Fig.  3, B–D). Therefore, to test whether the reduction in 
B cell development in the Gli3−/− FL is caused by an in-
crease in Hh proteins, we treated the Gli3−/− FLOCs with 
rHhip to neutralize endogenous Hh proteins. The proportion 
of CD19+ cells was significantly increased compared with the 
untreated Gli3−/− control (Fig. 3 E). This suggests that the re-
duction in B cell development in the Gli3 mutant was largely 
caused by an increase in Hh proteins in the FL and that Hh 
signaling negatively regulates B cell development in vitro.
B cell development in the Shh−/− fetus
To test whether Shh negatively regulates B lineage devel-
opment in vivo, we assessed B cell development in Shh−/− 
FLs. Most Shh−/− embryos die before E16, so we analyzed 
the E14.5 FL. Both Shh−/− and Shh+/− had significantly in-
creased percentages of CD19+ cells, B220+ cells, and of the 
CD19+B220+, CD19−B220+, and CD19+B220− populations 
compared with WT, with the heterozygote showing interme-
diate proportions (Fig. 4, A and B). The proportion of B lin-
eage–committed CD93+ cells and the proportion of CD93+ 
cells that were CD19+ were significantly increased in the 
Shh−/− FL compared with WT (Fig. 4 C). The proportion of 
CD19+BP1+ (Pre-B) cells was also significantly increased in 
the Shh−/− E14.5 FL compared with WT (Fig. 4 D).
As expected, the E14.5 Gli3-mutant FL showed the 
opposite phenotype, with significantly decreased CD19+, 
B220+, CD19+B220+, CD19+B220−, and CD19+BP1+ pop-
ulations compared with WT littermates (Fig. 4, E–G). Treat-
ment of E14.5 Shh−/− FLOCs with rShh for 4 d reduced 
to mean of WT littermates ± SEM, giving statistical significance by Student’s t test compared with WT littermate FL for: B220+ (Gli3−/−, P = 0.02), CD19+ 
(Gli3+/−, P = 0.03; Gli3−/−, P = 0.002), CD19+B220+ (Gli3+/−, P = 0.05; Gli3−/−, P = 0.001), CD19−B220+ (Gli3−/−, P = 0.02), CD19+B220− (E) and µH gated on 
CD19+ cells (Gli3+/−, P = 0.05; Gli3−/−, P = 0.001), from E17.5 and E18.5 Gli3+/− (n = 25), Gli3−/− (n = 14), and Gli3+/+ (n = 15). (G and H) Bar chart: mean ± 
SEM of FL populations, relative to mean of WT littermates, giving statistical significance by Student’s t test for Gli3−/− (n = 4) and WT (n = 3), where G shows 
percentage of CD93+ cells (Gli3−/−, P = 0.008) and H shows four populations, gated on CD93+. For fraction A (Fr.A): Gr1−, Mac1−, Ter119−, CD71−, ckit+, and 
CD127+ (P = 0.03); fraction B/C: CD19+, HSA+, CD43+, and BP-1−; fraction D: CD19+, HSA+, CD43+, and BP-1+ (P = 0.03); and fraction E: CD19+HSA+μH+ (P = 
0.002). (I) Bar chart: mean ± SEM of Q-RT-PCR analysis of VDJ recombination in FACS-sorted FL CD19+ cells from WT (n = 4) and Gli3−/− (n = 4) littermates, 
normalized relative to HS5 primers for two different VDJ recombination transcripts: VHJ558-Fw and JH1R, and VH7183-Fw and JH3R5. au, arbitrary units. 
(J) Flow cytometry profile of E17.5 FLs from control (Gli3fl/flVavCre−) and Gli3coKo (Gli3fl/flVavCre+) littermate embryos from a representative experiment. 
(K and L) Bar charts: mean percentage, relative to mean of WT littermates ± SEM, of B220+, CD19+, CD19+B220+, CD19−B220+, CD19+B220− (K) and BP-1+ 
gated on CD19+ cells (L), from Gli3coKO (Gli3fl/flVavCre+; n = 8) and control (Gli3fl/flVavCre−; n = 8) littermates. There were no significant differences by 
Student’s t test. *, P ≤ 0.05; **, P ≤ 0.01.
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Figure 2. Expression of Hh pathway components and active Hh signaling in E14.5 and E17.5 Wt and Gli3-mutant FL. (A–H) Bar charts: Repre-
sentative experiments show mean ± SEM (n = 3) of Q-RT-PCR analysis from WT, Gli3+/−, and Gli3−/− littermates for whole FL Gli1 (A), Gli2 (B), and Ptch1 (C) 
on E17.5 and Shh on E14.5 (D) and for FACS-sorted CD19+ and CD45− (stromal) cells for Gli1 (E), Gli2 (F), Ptch1 (G), and Shh (H). au, arbitrary units. (I–M) 
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the proportion of CD19+ cells compared with the untreated 
control FLOCs (Fig.  4 H), confirming that Shh negatively 
regulates B cell development.
As Shh inhibited B cell development in B-committed 
populations, we investigated the impact of Shh deletion and 
Gli3 deletion on the development of CLPs. We analyzed 
the proportion of CLPs, defined by the surface markers 
Lin−CD117+CD127+, and found a significant increase in the 
CLP population in the Shh-deficient FL and decrease in the 
Gli3-deficient FL, relative to their WT littermates (Fig. 4 I). 
Collectively, our experiments indicate that Gli3 and Shh influ-
ence B cell development from the CLP populations through 
to the CD19+B220+pre-BCR+ stage of development.
conditional deletion of Shh from the 
hematopoietic compartment of the FL does not 
increase B cell development
To investigate whether the increase in B cell development in 
the E14.5 Shh−/− FL is caused by cell-intrinsic loss of Shh 
expression in the hematopoietic compartment or caused by 
loss of Shh secretion by the nonhematopoietic compartment 
(stroma), we used the Cre-loxP system to conditionally de-
lete Shh from the hematopoietic lineage in Shhfl/flVavCre+ 
(ShhcoKO) embryos. We found no significant differences in 
B cell differentiation between the control (Cre negative) and 
ShhcoKO E14.5 FL and no significant differences in the pro-
portions of cells that expressed CD19, B220, and BP-1 and 
in the proportion of CLPs between control and ShhcoKO 
(Fig.  5, A–C). We likewise found no significant differences 
in B cell populations defined by cell surface expression of 
CD19, B220, and µH on E16.5 and E18.5 and no significant 
difference in the proportion of CLPs on E18.5 between Shh-
coKO and WT (Fig. 5, D–H). Therefore, it is Shh expression 
by the FL stroma, rather than hematopoietic cell–intrinsic 
Shh expression, that regulates B cell differentiation. This is 
consistent with the increase in Shh expression observed in the 
Gli3−/− FL stroma compared with WT (Fig. 2 H) and with 
the fact that conditional deletion of Gli3 from the hemato-
poietic compartment has no influence on B cell differentia-
tion (Fig. 1, J–L). Collectively, these experiments indicate that 
Gli3 activity in the FL stroma promotes B cell development 
by repression of Shh expression in the stroma.
Gli3 mutation inhibits transcription of B cell–lineage 
commitment, signaling, and maturation genes
To investigate the mechanisms of action of Gli3 on B cell de-
velopment, we measured transcription in developing B cells 
in the Gli3-mutant FL. We used RNA sequencing to analyze 
whole-genome expression in FACS-sorted CD19+B220+ FL 
B cells in the WT and Gli3 mutants. First, we analyzed the 
dataset in an unbiased manner using principal component 
analysis (PCA). The dataset segregated by genotype on both 
principal component axis 1 (PC1) and PC3 (Fig. 6 A). PC1, 
the axis attributing to the largest differences in the dataset 
(60% variability), separated the WT from the Gli3 mutants 
(Gli3+/− and Gli3−/−), whereas PC3 showed differences be-
tween Gli3+/− and Gli3−/− (Fig. 6 A).
Further analysis of the genes with high positive and 
negative scores on PC1 showed that PC1 reflected differences 
in genes associated with Hh signaling and genes associated 
with B cell signaling and differentiation. Key Hh signaling 
and target genes, including Gli1, Hdac3, and Smo, had pos-
itive PC1 scores, indicating that the expression of these is 
higher in the Gli3 mutant. In contrast, genes that were lower 
in the Gli3 mutants had high negative PC1 scores and were 
mainly B cell–signaling and –lineage commitment genes. 
Thus, not only did Gli3 mutation reduce the proportion of 
CD19+B220+ B-committed cells in the FL, but also, within 
that sorted population, expression of genes required for B cell 
differentiation was reduced.
To understand better the genome-wide differences in 
the dataset, we intersected the differentially expressed genes 
identified by Ebayes statistics with the genes identified by 
PCA. We selected the 3,000 genes (highest and lowest scorers) 
that contributed most to the PC1 axis and intersected these 
with the 3,000 most significantly differentially expressed genes 
by Ebayes statistics (Table S1). The resulting 1,122 genes were 
clustered, and a heat map showing their gene expression was 
drawn (Fig. 6, B and C). This intersection highlighted genes 
that have been previously shown to be Shh-target genes in 
other tissues, such as Stmn1, Hmgb1, Hmgb2, Hoxa4, Cul4a, 
and Bmi1, which were all up-regulated in the Gli3 mutant 
(Fig. 6 C; Itou et al., 2011; Wang et al., 2012; Lu et al., 2015; 
Yang et al., 2015). In contrast, master regulators of early B 
cell development Ebf1 and Foxo1 were down-regulated in 
the Gli3 mutants compared with WT, and several other B 
lineage differentiation and maturation genes, including Klf13, 
Egr1, Irf1, Irf4, and Cd69, were also lower in the Gli3 mu-
tant (Gururajan et al., 2008; Lu, 2008; Outram et al., 2008). 
B cell activation and signaling genes including genes in-
volved in modulating MAPK signaling such as Dusp1, Dusp2, 
Map3k3, MapKapk2 (Lang et al., 2006), and canonical 
NF-κB signaling genes (Nfkbid, Nfkbiz, and Tnfaip3) were 
all down-regulated in the Gli3 mutant. In addition, the AP1 
Flow cytometric analysis of GFP expression in GBS-GFP–reporter transgenic E17.5 FL from WT, Gli3+/−, and Gli3−/− littermates. (I) Dot plots: SSC versus 
GFP fluorescence, gated on CD19+ cells. (J and K) Histograms: expression of GFP in CD19+B220− (J) and CD19−B220+ (K) in the Gli3+/+ and Gli3−/− E17.5 FL. 
(L) Histograms: expression of GFP in the E17.5 WT FL stroma (CD45−; left) and CD45–epithelial cell adhesion molecule (EPC AM)+ stromal cells (right). (M) 
Bar charts: mean percentage and mean MFI ± SEM of GFP fluorescence in CD19+ cells, relative to the mean of WT. Gli3+/−, n = 4; Gli3−/−, n = 3; WT, n = 3. 
Differences are statistically significant by Student’s t test, compared with WT; for percentage of GFP+ in the CD19+ cells, for Gli3−/−, P = 0.002, and for the 
MFI of GFP on the CD19+ cells, for Gli3+/−, P = 0.03 and, for Gli3−/−, P = 0.04. *, P ≤ 0.05; **, P ≤ 0.01.
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components Fosb, Jun, and Junb, required for pre-BCR signal 
transduction (de Gorter et al., 2007), and Klf2, an essential 
late target gene of the pre-BCR, were also lower in the Gli3 
mutant (Winkelmann et al., 2014).
As both pre-BCR/BCR signaling and IL-7 signaling 
are important regulators of B cell development, we compared 
expression levels of genes that encode downstream compo-
nents of these signaling pathways or are their immediate tran-
Figure 3. Modulation of B cell development by rShh and rHhip treatment of Wt and Gli3−/− FLocs. (A–E) WT E17.5 FLOCs were treated with 
recombinant proteins, as stated, for 4 d and analyzed by flow cytometry. n = 4. (A) Dot plots: SSC versus CD19 staining in control (untreated) and treated 
with rShh, rHhip, and rShh + rHhip. (B) Bar charts: mean ± SEM, relative to the mean of control untreated FLOCs from littermates, showing statistical 
significance by Student’s t test compared with untreated for CD19+ cells (rShh treatment, P = 0.002; rHhip treatment, P = 0.04; left), and CD19+B220+ cells 
(rShh treatment, P = 0.002; rHhip treatment, P = 0.04; right). The dotted line indicates mean of untreated control WT. (C) Dot plots: µH+ gated on the CD19+ 
population in control (untreated) and treated with rShh, rHhip, and with rShh and rHhip together. (D) Bar chart: mean ± SEM, relative to the mean of control 
untreated FLOCs showing statistical significance by Student’s t test compared with untreated for µH+ gated on the CD19+ population (rShh treatment, P = 
0.03). The dotted line indicates mean of untreated control WT. (E) Gli3−/− FLOCs treated with rHhip and control untreated Gli3−/− FLOCs were cultured for 4 
d. Dot plots: SSC versus CD19 staining. Differences in the mean percentages were statistically significant between rHhip treatment and control untreated. 
P = 0.02 for CD19+ cells, and P = 0.03 for CD19+B220+ cells. *, P ≤ 0.05; **, P ≤ 0.01.
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Figure 4. B cell development in the E14.5 Shh-deficient and Gli3-deficient FL and Shh−/− FLoc. (A–D) Flow cytometry of E14.5 FLs from Shh+/+ 
(WT), Shh+/−, and Shh−/− littermates. (A) Dot plots: SSC against CD19 staining (top) and CD19 staining against B220 staining (bottom). (B) Bar charts: rel-
ative mean percentage ± SEM, relative to the mean of WT littermates for Shh−/− (n = 7), Shh+/− (n = 10), and WT (n = 4) of populations stated, showing 
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scriptional targets (Fig. 6 D). Expression levels of many genes 
involved in pre-BCR/BCR signal transduction (Dusp1-3, 
Tnfaip3, Nfkbid, and the AP-1 components Junb and Fosb) 
were lower in the Gli3−/− datasets than WT, as were its im-
mediate transcriptional targets CD69 and Egr1 (Fig. 6 D). We 
observed no difference in expression in Tcf3 (E2A) between 
genotypes (Fig.  6  D) or in IL7r, Il2rg, Stat5a, Stat5b, and 
Pik3ca (components of the IL-7/thymic stromal lymphopoi-
etin signaling pathway) or in Myb, Bcl2, or Bcl2l1 (transcrip-
tional targets of IL-7 signaling in B-lineage cells; Fig. 6 E).
We did not detect Shh expression in any dataset (Fig. 6 E), 
consistent with the Q-RT-PCR showing Shh up-regulation in 
Gli3−/− FLs being restricted to stromal cells and not B-lineage 
cells (Fig. 2 H) and with the fact that conditional deletion of Shh 
from B-lineage cells had no impact on their development (Fig. 5).
Together these analyses indicate that the Gli3-mutant 
B220+CD19+ population has increased Hh-dependent tran-
scription, consistent with our previous results showing in-
creased Shh transcription in the Gli3-mutant FL stroma 
(Fig. 2 H) and increased Hh signaling in Gli3−/− B-lineage 
cells (Fig. 2, G, I–K, and M). Gli3 deficiency also decreased 
transcription of genes required for B cell differentiation, mat-
uration, and signaling within the sorted B220+CD19+ pop-
ulation. Thus, increased Shh signaling reduced transcription 
of regulators of B lineage commitment and differentiation. 
Therefore, we investigated whether Shh treatment can di-
rectly down-regulate transcription of the key B-lineage tran-
scription factors Ebf1 and Pax5 in vitro.
Shh signaling leads to reduced Ebf1 and Pax5 expression 
during B lineage development
Ebf1 and Pax5 are master regulators of B-lineage commit-
ment and B cell development. B cell–lineage commitment 
from the CLP stage is regulated by Ebf1 (Zhang et al., 2003), 
which promotes its own transcription as well as Pax5 tran-
scription. Pax5 further increases Ebf1 transcription (Roessler 
et al., 2007) creating a positive feedback loop between itself 
and Ebf1. This mechanism allows Ebf1 and Pax5 to regulate 
B cell development and maturation. Therefore, we tested 
whether the increase in Shh in the Gli3 mutant influences 
Ebf1 and Pax5 expression during B cell development.
First, we measured overall Ebf1 and Pax5 transcription 
in the Gli3-mutant E17.5 FL and found a reduction in both 
Gli3+/− and Gli3−/− relative to WT (Fig. 7 A), consistent with 
the RNA sequencing data and the reduction in B cell devel-
opment. In contrast, we found an increase in the expression 
of both transcription factors in the Shh+/− and Shh−/− E14.5 
FL, consistent with increased commitment to the B lineage in 
the absence of Shh (Fig. 7 A).
Because the Gli3 mutant has increased Shh signal-
ing and rShh treatment decreased the CD19+ population in 
FLOCs, we tested whether we could influence both Pax5 and 
Ebf1 transcription and protein expression in vitro by mod-
ulating Hh signaling in FLOCs by treatment with rShh or 
rHhip over a 4-d culture period. We measured the expression 
of intracellular Pax5 and Ebf1 by FACS analysis to investigate 
protein expression in single cells. On day 1 after treatment, 
there were no significant differences in the proportions of 
Ebf1+Pax5− and Ebf1+Pax5+ cells (not depicted). However, 
a significant reduction in the proportion of Ebf1+Pax5+ cells 
was seen on days 2 and 4 of rShh treatment (Fig. 7 B). This 
Ebf1+Pax5+ population significantly increased and was sus-
tained in the rHhip-treated cultures, whereas the cultures in 
which both rShh and rHhip were added together were not 
different from the control cultures (Fig.  7  B). Comparison 
of the ratio of Ebf1+Pax5+ cells to Ebf1+Pax5− cells showed 
that rHhip treatment increased the ratio by twofold by day 4 
in culture, indicating that inhibition of Hh signaling acceler-
ated the transition from Ebf1+Pax5− cell to Ebf1+ Pax5+ cell. 
In contrast, rShh treatment reduced this ratio on both days 
2 and 4 of culture, suggesting that Shh signaling repressed 
the induction of Pax5 and the transition to Ebf1+Pax5+ cell. 
The changes in the Ebf1 and Pax5 proteins were consistent 
with the changes in transcription of Ebf1 and Pax5 on day 4 
(Fig. 7 C). In the Gli3−/− FL, the proportion of Ebf1+Pax5+ 
cells was reduced compared with WT, consistent with the 
Q-RT-PCR data (Fig. 7 D).
Then, we FACS sorted CD19+ cells from Gli3−/− and 
WT littermates and analyzed the expression of Ebf1 and Pax5. 
We observed a decrease in both Ebf1 and Pax5 transcription 
in purified CD19+ cells from the Gli3-mutant FL compared 
with WT (Fig. 7 E). Interestingly, the decrease in expression 
statistical significance compared with WT for CD19+ (Shh+/−, P = 0.03; Shh−/−, P = 0.002), B220+ (Shh+/−, P = 0.02; Shh−/−, P = 0.02), CD19+B220+ (Shh+/−, 
P = 0.03; Shh−/−, P = 0.02), CD19−B220+ (Shh−/−, P = 0.02), and CD19+B220− (Shh+/−, P = 0.02; Shh−/−, P = 0.002) cells. (C, top) Dot plot: SSC against CD93 
staining. (Bottom) histogram: CD19 staining gated on CD93. Both populations are statistically significant, relative to WT (P = 0.05 and P = 0.03, respectively). 
(D) Histogram: BP-1 staining gated on CD19. Bar chart: mean percentage ± SEM of this population, showing statistical significance relative to the mean 
of WT littermate for Shh−/− (P = 0.003). (E and F) Flow cytometry of E14.5 FL from Gli3+/+ (WT), Gli3+/−, and Gli3−/− littermates. For Shh−/−, n = 7; WT, n = 4. 
(E) Dot plots show SSC against CD19 staining (top) and CD19 staining against B220 staining (bottom). (F) Bar charts show the relative mean percentage ± 
SEM, relative to the mean of WT littermates of the populations stated, showing statistical significance relative to WT for B220+ (Gli3−/−, P = 0.04), CD19+ 
(Gli3+/−, P = 0.04; Gli3−/−, P = 0.003), CD19+B220+ (Gli3−/−, P = 0.003), CD19−B220+ (not significant), and CD19+B220− (Gli3+/−, P = 0.03; Gli3−/−, P = 0.003). 
For Gli3+/−, n = 10; Gli3−/−, n = 9; Gli3+/+, n = 7. (G) Histogram: BP-1 staining gated on CD19. Bar chart: mean percentage ± SEM of this population, showing 
statistical significance relative to the mean of WT littermates for Gli3−/− (P = 0.03). For Gli3−/−, n = 9; Gli3+/+, n = 7. (H) Shh−/− FLOCs were treated with rShh 
for 4 d. Bar chart: mean (relative to mean of control cultures) percentage ± SEM of CD19+ cells. The difference was statistically significant by Student’s t test 
(P = 0.008; n = 4). (I) Bar charts: mean percentage ± SEM of CD117+CD127+ CLP cells in E17.5 Gli3−/− (n = 9; P = 0.02) and E14.5 Shh−/− (n = 4; P = 0.002) 
FLs, relative to their respective WT littermates. Shaded bars are knockout, and unshaded bars are WT. *, P ≤ 0.05; **, P ≤ 0.01.
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Figure 5. B cell development in the Shhfl/flVavcre FL. (A–H) Flow cytometry of the E14.5 FL (A–C), E16.5 FL (D and E), and E18.5 FL (F–H) from Shhfl/
flVavCre− (E14.5, n = 5; E16.5, n = 3; E18.5, n = 5) and Shhfl/flVavCre+ (E14.5, n = 3; E16.5, n = 5; and E18.5, n = 3) littermates. (A, D, and F) Dot plots: SSC 
against CD19 staining (left), CD19 staining against B220 staining (middle), and µH staining for D and F (right). (B, E, and G) Bar charts: mean percentage, 
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of both Ebf1 and Pax5 in the sorted Gli3−/− CD19+ cells was 
more pronounced than the reduction in transcript expression 
in the unsorted FL and was also greater than the proportional 
change in the CD19+ population in the Gli3−/− FL compared 
with WT. This was consistent with the action of Shh to re-
duce B cell development in FLOCs, in which the magnitude 
of the reduction in Pax5 and Ebf1 transcription was greater 
than the change in the Ebf1+Pax5+ population (Fig. 7, B and 
C) and also greater than the magnitude of the change in the 
overall proportion of B-lineage cells caused by Shh treatment 
(Fig. 3 A). Thus, Shh treatment in vitro or Gli3 deficiency 
in vivo not only reduced the proportion of CD19 cells that 
were present, but also led to a reduction in transcription of 
the key B-lineage master regulators Ebf1 and Pax5 within 
the B lineage–committed population, most likely by signaling 
to up-regulate the transcription of an intermediate transcrip-
tional repressor of Ebf1 and/or Pax5.
To investigate the relationship between Hh-mediated 
transcription and the reduction in transcription of Ebf1 and 
Pax5, we measured intracellular Ebf1 and Pax5 expression 
in rShh-treated and control untreated GBS-GFP–transgenic 
FLOCs. We found that >62% of Ebf1+Pax5− cells expressed 
high levels of GFP, indicating that this population actively 
mediates Hh-dependent transcription, which is therefore 
compatible with Ebf1 protein expression (Fig.  7  F). These 
cells are the earliest B cell population that differentiates from 
the CLP stage (Egawa et al., 2001; Mebius et al., 2001). In-
terestingly, GFP expression was reduced to <0.3% in the later 
Ebf1+Pax5+ population (Fig. 7 F), indicating that Hh signal-
ing decreases as cells become more mature and that, once 
Pax5 is expressed, very few cells are undergoing Hh-mediated 
transcription. This is consistent with Shh signaling acting di-
rectly or indirectly to inhibit Pax5 transcription. The Ebf1+-
Pax5− population was Hh responsive, as expression of GFP 
in the Ebf1+Pax5− population was increased on rShh treat-
ment, with the proportion of GFP-negative cells decreasing 
from ∼38% to ∼28%. In contrast, GFP was not induced by 
rShh treatment in the Pax5+Ebf1+ population during the 2-d 
culture, and the proportion of GFP-negative cells remained 
>99.7% under both conditions.
Collectively, our experiments indicate that the 
Gli3-mutant FL had increased Hh signaling resulting in de-
creased B cell development. Furthermore, loss of Shh in vitro 
and in vivo led to increased B-lineage commitment and de-
velopment. We propose that Shh signaling either directly or 
indirectly represses Pax5 expression (most likely by transcrip-
tional activation of a transcriptional repressor of Pax5) and 
that this leads to loss of Pax5’s induction of Ebf1, reduction in 
both Pax5 and Ebf1 expression, and therefore to the negative 
regulation of the B lineage development observed.
dIScuSSIon
Here, we showed that Gli3, expressed by the stromal com-
partment, is required for B cell development in the FL. 
Mutation of Gli3 led to an overall reduction in B lineage–
committed cells, reduction in the proportion of pre–B cells, 
and reductions in CLPs and both the CD19+B220− B1 
progenitor population on E14.5 and the CD19−B220+ B2 
progenitor population on E17.5. Gli3 mutation additionally 
reduced expression of B lineage–specifying and –signaling 
genes within the B220+CD19+ population, indicating that 
the effect of Gli3 mutation is not entirely caused by its in-
fluence on CLPs and the earliest B cell progenitors but that 
it continues to influence the more mature B lineage–com-
mitted population. The changes in B cell differentiation in 
the Gli3-mutant FL could be caused by Hh-dependent or 
Hh-independent effects. We found that loss of Gli3 led to 
increased Shh expression and overall increased Hh signaling 
in the mouse FL. Thus, Gli3 was acting as a repressor of the 
Hh pathway in the FL, as observed in the development of 
other cells and tissues, such as the neural stem cells, verte-
brate limb bud, and thymus (te Welscher et al., 2002; Hag-
er-Theodorides et al., 2009; Petrova et al., 2013; Saldaña et 
al., 2016). Treatment of Gli3-deficient FLOCs with rHhip 
(to neutralize endogenous Hh proteins) increased B cell de-
velopment, and therefore, the reduction in B cell develop-
ment in the Gli3 mutants was Hh dependent and caused by 
increased Shh expression in the Gli3−/− FL.
In contrast, the Shh-deficient FL had increased B lin-
eage commitment and B cell differentiation, demonstrating 
that Shh negatively regulates B cell development in vivo. We 
showed that both Shh transcription in FL stroma and Hh sig-
naling to B-lineage cells are increased in the Gli3-deficient FL 
and that Shh negatively regulates B cell development by sig-
naling directly to developing hematopoietic cells, as Hh-target 
genes were up-regulated in the Gli3−/− CD19+B220+ popu-
lation, and the Hh-reporter transgenic FL showed increased 
GFP expression in the Gli3−/− CD19+ population.
Expression of the master regulators of B cell develop-
ment, Ebf1 and Pax5, was reduced in the Gli3-deficient FL 
but increased in the Shh-deficient FL, and treatment of WT 
FLOCs with Hhip to neutralize endogenous Hh molecules 
in the cultures increased the proportion of Ebf1+Pax5+ cells 
and increased transcription of both Ebf1 and Pax5 within the 
CD19+ population, whereas rShh treatment had the opposite 
effect. The Ebf1+Pax5− population showed high Hh-mediated 
transcription in the Hh-reporter transgenic FL, and there-
fore, we proposed that Shh signaling within the Ebf1+Pax5− 
cells reduced expression of Pax5, thereby also reducing the 
Pax5-dependent induction of Ebf1 expression, leading to an 
overall reduction in B cell development.
relative to mean of WT littermates ± SEM of the B220+, CD19+, CD19+B220+, CD19−B220+, CD19+B220−, CD19+BP-1+, and CD19+µH+ populations. (C and 
H) Bar charts: mean percentage ± SEM of Lin−CD117+CD127+ CLPs. There were no significant differences by Student’s t test. Shaded bars are Cre+, and 
unshaded bars are Cre−.
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Figure 6. rnA sequencing detects transcriptional differences in Hh signaling genes and B cell differentiation and signaling genes between 
the Wt and Gli3-mutant cd19+B220+ cells. (A) PCA showing sample relationships in PC1 and PC3 for WT (n = 2), Gli3+/− (n = 2), and Gli3−/− (n = 2) 
CD19+B220+ populations from E17.5 FLs. (B) Venn diagram: 1,122 genes intersect out of the 3,000 genes that contributed most to PC1 (highest and lowest 
scoring genes) and the 3,000 most significant differentitally expressed genes by Ebayes statistics. (C) Gene expression heat map showing Hh signaling genes 
in blue and B cell differentiation and signaling genes in black. Normalized expression signals are represented as a z score where green is lower expression 
and red is higher expression levels. (D and E) Transcript expression (reads per million kilobases) of pre-BCR/BCR signaling and target genes (D) and Shh, IL-7, 
and IL-7/thymic stromal lymphopoietin (TSLP) signaling and target genes (E) in the Gli3−/− (green; n = 2) and WT (blue; n = 2) RNA sequencing datasets.
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Figure 7. Expression of Pax5 and Ebf1 in the FL. (A) Representative experiment showing mean ± SEM (n = 3) of Q-RT-PCR for Pax5 and Ebf1 in FLs 
from Gli3 and Shh mutants compared with WT littermates. au, arbitrary units. (B and C) WT FLOCs (n = 3) were treated with rShh, rHhip, and rShh + rHhip 
for 2 and 4 d, compared with untreated control cultures, and analyzed by flow cytometry and Q-RT-PCR. (B) Dot plots: anti-Ebf1 and anti-Pax5 staining 
on day 2 (top) and day 4 (bottom). Charts: ratio of Ebf1+Pax5+ to Ebf1+Pax5− cells in the different culture conditions on day 2 (top) and day 4 (bottom). 
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Shh signaling from follicular dendritic cells to B cells in 
the adult spleen has been shown to promote B cell survival 
and function (Sacedón et al., 2005), and in the adult BM, 
components of the Hh signaling pathway are expressed in 
developing B cells (Heng et al., 2008; Cooper et al., 2012). 
However, conditional deletion of Smo from the B cell lin-
eage did not influence B cell development in the adult BM 
(Cooper et al., 2012). Our study demonstrates that the Hh 
signaling pathway is active in developing fetal B cells and reg-
ulates B cell development in the FL. Therefore, there may 
be tissue- or life stage–specific differences in the function of 
Hh signaling between FL and adult BM. Alternatively, it is 
possible that Hh pathway activation is noncanonical (Smo 
independent) in B-lineage cells, which do not have primary 
cilia, or that a balance between canonical and noncanoni-
cal signaling may exist, as described in osteoblast differentia-
tion (Yuan et al., 2016).
Our genome-wide RNA sequencing data from the 
sorted CD19+B220+ population in the Gli3 mutants revealed 
many differentially expressed genes between Gli3−/− and WT. 
Many Hh-target genes (e.g., Stmn1, Hdac3, Hoxa4, Hmgb2, 
Bmi1, and Cul4a) were up-regulated in the Gli3 mutants, 
consistent with the increased Hh-mediated transcription 
measured using the GBS-GFP reporter and confirming that 
Shh signals directly to developing B cells.
In contrast, many B cell signaling pathway genes in-
volved in NF-κB activity (Nfkbid, Nfkbiz, and Tnfaip3), 
MAPK signaling (MapKapk2 and Map3k3), and components 
of AP-1 (Junb and Fosb) were decreased in the Gli3 mutant. 
These pathways are required for pre-BCR and BCR signal-
ing (Feng et al., 2004; de Gorter et al., 2007). In addition, 
Tnfaip3 regulates marginal zone and B1 cell development in 
the adult (Chu et al., 2011), and we observed a reduction 
in B1 progenitor cells in the E14.5 Gli3−/− FL. Interestingly, 
Hh-mediated transcription in developing and mature T cells 
also represses expression of genes that regulate activity of 
NF-κB, MAPK, and AP1, leading to reduced pre-TCR and 
TCR signaling (Rowbotham et al., 2007, 2009; Furmanski et 
al., 2012, 2015; Barbarulo et al., 2016).
In addition to the decreased transcription of genes 
associated with pre-BCR and BCR signaling, the RNA 
sequencing revealed a significant decrease in key transcrip-
tional regulators of B cell differentiation including Ebf1, 
Foxo1, Runx1, and Irf4 (Dengler et al., 2008; Niebuhr et al., 
2013). Ebf1 is required from the early CLP stage to the late 
mature stages of B cell development (Roessler et al., 2007; 
Nechanitzky et al., 2013) and, importantly, activates transcrip-
tion of another key master regulator of B cell development, 
Pax5. Then, Pax5 promotes Ebf1 transcription, creating a pos-
itive feedback loop, which supports all stages of B cell devel-
opment (Roessler et al., 2007).
We found high Hh pathway activity (measured by GFP 
expression in the Hh-reporter embryo) in Ebf1+Pax5− cells, 
but GFP expression ceased in the next Ebf1+Pax5+ popula-
tion. Both Ebf1 and Pax5 protein and gene expression were 
reduced by rShh treatment and increased by neutralization of 
Hh proteins by rHhip treatment in FLOCs, and manipulation 
of Hh signaling influenced the transition from Ebf1+Pax5− 
to Ebf1+Pax5+ cell. Therefore, we propose that Shh signaling 
to developing B cells functions to reduce Pax5 expression, 
which then breaks the positive feedback loop, leading to re-
duction in Ebf1 expression. Interestingly, Shh signaling has 
been shown to interact with and regulate other Pax family 
members in the development of other tissues (Chi and Ep-
stein, 2002; Blake and Ziman, 2014).
Dysregulated Hh pathway activation is involved in 
some B cell malignancies (Dierks et al., 2007; Lin et al., 2010), 
including B cell acute lymphoblastic leukemia (B-ALL; 
Ramirez et al., 2012; Qu et al., 2013), a common cancer of 
early childhood, and microarray expression profiles show that 
Hh pathway components are expressed in human FL and BM 
(Fig. S1 A; Su et al., 2004). Understanding the function of Hh 
signaling in normal fetal B cell development and its effect on 
Pax5 and Ebf1 expression will be important to our under-
standing of its role in B-ALL. In the future, it will be import-
ant to investigate how dysregulated Hh signaling influences 
Pax5 and Ebf1 activity in B-ALL.
In summary, we show that Gli3 activity in the FL stroma 
is required for normal B cell development. We showed that 
Shh signaling directly to B-lineage cells negatively regu-
lates their development.
MAtErIALS And MEtHodS
Mice
C57BL/6 mice were purchased from Envigo. GBS-GFP–
transgenic (GBS-GFP-tg) mice were provided by J. Briscoe 
(Crick Institute, London, England, UK; Balaskas et al., 2012), 
Vav-iCre-tg by D. Kioussis (National Institute for Medical 
Research, London, England, UK; de Boer et al., 2003), and 
Shh+/− mice by P. Beachy (Stanford University School of 
Medicine, Palo Alto, California; Chiang et al., 1996) and were 
backcrossed for >12 generations on C57BL/6 mice. Gli3fl/
fl, Shhfl/fl, and Gli3+/− mice on C57BL/6 background were 
purchased from The Jackson Laboratory. Time mates were 
obtained by mating overnight, and the next day was counted 
as E0.5. Mice were bred and maintained at University Col-
(C) Bar charts: representative experiment showing mean ± SEM (n = 3) of Q-RT-PCR for Pax5 and Ebf1 on day 4 of WT FLOCs treated with rShh or rHhip and 
control untreated. (D) Dot plots: anti-Pax5 and anti-Ebf1 staining in Gli3+/+ and Gli3−/− littermate FLs. (E) Representative experiment showing mean ± SEM 
(n = 3) of Q-RT-PCR for Pax5 and Ebf1 in purified CD19+ cells from Gli3+/+ and Gli3−/− E17.5 FLs. All transcript expression levels were normalized relative 
to HPRT. (F) Histograms: GFP expression in Ebf1+Pax5− and Ebf1+Pax5+ cells in the E17.5 GBS-GFP–transgenic FLOCs, control (continuous lines), and rShh 
treated (dotted lines) FLs, cultured for 2 d.
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lege London under UK Home Office regulations, and ex-
periments were approved by the University College London 
ethical approval committee.
Flow cytometry, antibodies, and cell purification
FL cell suspensions were made by crushing each FL between 
two frosted slides. Where stated, red blood cells were lysed 
using 1× RBC lysis buffer (eBioscience) according to the 
manufacturer’s instructions. Cells were stained as described 
previously (Hager-Theodorides et al., 2005) using directly 
conjugated antibodies from BD, BioLegend, and eBioscience. 
Data were acquired on a C6 Accuri flow cytometer (BD) and 
analyzed using FlowJo software (Tree Star). Live cells were 
gated by forward scatter and side scatter (SSC) profiles. The 
data represent at least three experiments. In some experi-
ments, CD19+ cells were purified using the EasySep biotin 
magnetic bead positive selection kit (STE MCE LL Technolo-
gies) according to the manufacturer’s instructions, and RNA 
was extracted for Q-RT-PCR analysis.
FLocs
FLs were extracted from embryos at different stages of de-
velopment. They were cut into ∼1-mm cubes and cultured 
on 0.8-µm filters (EMD Millipore) in 1 ml of AIM-V se-
rum-free medium (Invitrogen) in 24-well plates for up to 
4-d at 37°C and 5% CO2 before analysis. In some exper-
iments, rHhip (Sigma-Aldrich) or rShh (R&D Systems) 
was added at 1 µg/ml. To allow comparison between litters 
for statistical analysis, relative numbers or percentages for 
each genotype or treatment were calculated by dividing by 
the mean of controls from the same litter (untreated con-
trol or WT littermates).
rnA sequencing and data analysis
FL from WT, Gli3+/−, and Gli3−/− embryos (n = 2) were dis-
sected on E17.5 and crushed between two frosted slides. The 
cell suspension was stained using the antibodies CD19-APC 
and B220-PeCy7, and the double-positive B220+CD19+ 
population was FACS sorted. RNA from this population was 
extracted using an Arcturus PicoPure RNA Isolation kit (Ap-
plied Biosystems), and quantity and quality were determined 
by a Bioanalyzer 2100 (Agilent Technologies).
RNA was sequenced by University College London 
Genomics on a NextSeq 500 system (Illumina). The se-
quenced data are publically available in the GEO database 
under accession no. GSE81467. The RNA sequencing dataset 
was processed and standardized using the Bioconductor pack-
age DESeq2. The Bioconductor package DESeq2 was used 
to generate normalized estimates of transcript abundance, 
expressed as RPKM (reads per kilobase of transcript per mil-
lion mapped reads). Differentially expressed genes were de-
termined using the moderated Ebayes t statistic P < 0.05 from 
the limma package in Bioconductor. PCA was performed 
using the CRAN package ade4.
Q-rt-Pcr
RNA extraction and cDNA synthesis were performed as de-
scribed previously (Sahni et al., 2015). We used the Quan-
tiTect primers for Gli1, Gli2, Shh, Hhip, Gli3, Smo, Ptch1, 
Ebf1, and Pax5 from QIA GEN. The cDNA samples were 
prepared using the iQ SYBR Green Supermix (Bio-Rad 
Laboratories) according to the manufacturer’s instructions 
and run on a iCycler system (Bio-Rad Laboratories). Gene 
transcript levels were normalized relative to HPRT.
For quantification of VH to JH rearrangements, we pre-
pared RNA from FACS-sorted CD19+ cells from Gli3−/− and 
WT E17.5 FL and followed the protocol described by Braikia 
et al. (2014), using the primers combinations: VH7183-Fw 
and JH1R; VHJ558-Fw and JH1R; and HS5-Fw1 and 
HS5-R1 for normalization.
Pcr analysis for genotyping
DNA for PCR analysis was extracted from tissues by digest-
ing in lysis buffer containing 50 mM KCl, 1.5 mM MgCL2, 
10  mM Tris HCL, pH 8.5, 0.01% gelatin, 0.45% Nonidet 
P-40, 0.45% Tween 20, and 0.5 µg/ml proteinase K (Sig-
ma-Aldrich) in water. Approximately 1 µg DNA was used as 
a template in each PCR reaction, using primers for Shh−/−, 
Shh+/−, and Shh+/+ as described by Shah et al. (2004). Gli3+/+, 
Gli3+/−, and Gli3−/− were distinguished phenotypically 
(Johnson, 1967), and genotype was confirmed by PCR as 
previously described (Hager-Theodorides et al., 2005). Gli3fl/
fl, Shhfl/fl, and Vav-iCre-tg mice were genotyped as previously 
described (Saldaña et al., 2016).
Statistical analysis
Statistical analysis was performed using unpaired two-tailed 
Student’s t tests, and probabilities were considered significant 
if P ≤ 0.05 (*), P ≤ 0.01 (**), or P ≤ 0.001 (***).
online supplemental material
Fig. S1 represents the transcript expression of Hh pathway 
members (GLI1, GLI2, GLI3, PTCH1, SMO, and SHH) in 
the human BM and FL and shows transcript expression of 
Hh molecules (Shh, Ihh, and Dhh) and pathway components 
Gli1, Gli2, Gli3, Ptch1, and Smo from the ImmGen database 
in mouse FL. Table S1 is available as an Excel file and contains 
a list of 3,000 differentially expressed genes, significant by 
Ebayes statistics, 1,500 genes with high positive PC1 scores, 
and 1,500 genes with high negative PC1 scores.
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